HANS-PETER GERBER, Ph.D
Chief Scientific Officer
“Biology is the foundation for therapy and is the guiding principle for the design of our next generation of ADC therapeutics.”
Dr. Hans-Peter Gerber brings 30 years of R&D experience in oncology drug development, specializing in antibody-drug conjugates (ADCs), redirected T-cell targeting compounds (bispecifics), and adoptive T-cell therapies (TCR-T and CAR-T cells). He has built successful drug development teams across pharma, biotech, and startups, overseeing preclinical development with low clinical attrition rates. Notably, he has contributed to the development of 6 of the 15 approved ADCs.
In September 2023, Hans-Peter joined Sutro Biopharma as CSO, leading a research team of 80 FTEs. He co-founded Codeable Therapeutics in 2022, focusing on next-generation ADCs that induce immunogenic cell death, and successfully secured seed funding in 2023.
Hans-Peter also serves as Chairman of the Board at T-CURX, a startup in Wuerzburg, Germany, developing next-generation CAR-T cell therapies, and serves as a board member at Athebio in Zurich, Switzerland, which develops biotherapeutic compounds using Darpin technology.
From 2018 to 2022, he was CSO and SVP at 3T Biosciences, where he expanded the research organization to over 30 FTEs and raised over $50M in an oversubscribed Series A round as interim CEO. He also served as an independent director at NBE Therapeutics, acquired by Boehringer Ingelheim for $1.5B in 2021.
Previously, Hans-Peter built the R&D organization at Maverick Therapeutics, leading to its acquisition by Takeda for $525M in 2021. He is a consultant to VC firms, evaluating therapeutic modalities including ADCs, bispecifics, and T-cell programs.
Between 1995 and 2017, Hans-Peter held increasing responsibilities at Genentech, Seattle Genetics, and Pfizer, overseeing multiple oncology biotherapeutic programs from discovery through IND filings. His work led to over 10 IND filings, including 7 ADCs and contributions to 3 BLAs, including Avastin and 2 ADCs (Mylotarg, Besponsa).
As an internationally recognized leader in oncology R&D, Hans-Peter has authored over 100 peer-reviewed papers and holds over 100 patents. He received his MS in Biochemistry and PhD in Molecular Biology from the University of Zurich, Switzerland
